Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
15.27
+0.13 (0.86%)
Oct 10, 2025, 4:00 PM EDT - Market closed
Forte Biosciences Employees
Forte Biosciences had 14 employees as of December 31, 2024. The number of employees increased by 5 or 55.56% compared to the previous year.
Employees
14
Change (1Y)
5
Growth (1Y)
55.56%
Revenue / Employee
n/a
Profits / Employee
-$3,032,286
Market Cap
272.31M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | 5 | 55.56% |
| Dec 31, 2023 | 9 | 3 | 50.00% |
| Dec 31, 2022 | 6 | 1 | 20.00% |
| Dec 31, 2021 | 5 | -4 | -44.44% |
| Dec 31, 2020 | 9 | 8 | 800.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FBRX News
- 8 days ago - Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Business Wire
- 26 days ago - Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium - Business Wire
- 2 months ago - Forte Biosciences, Inc. Announces Results and Provides Update - Business Wire
- 3 months ago - Forte Biosciences Announces Pricing of $75 Million Public Offering - Business Wire
- 3 months ago - Forte Biosciences Announces Proposed Public Offering - Business Wire
- 3 months ago - Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study - Business Wire
- 6 months ago - Forte Biosciences, Inc. Announces Results and Provides Clinical Update - Business Wire
- 8 months ago - Forte Biosciences, Inc. to Present at Upcoming Investor Meetings - Business Wire